Kite's shares fly high after cancer drug clears main study goal
(Reuters) - Kite Pharma Inc said on Tuesday its experimental CAR T-cell therapy, which helps the immune system fight cancer, was highly effective in treating aggressive non-Hodgkin's lymphoma, meeting the main goal of a key study.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
More News: Cancer | Cancer & Oncology | Health | Lymphoma | Non-Hodgkin's Lymphoma | Pharmaceuticals | Study